Spain's Grifols to Test Plasma Therapy for COVID-19 With U.S. FDA

26 Mar, 2020

Spain's Grifols has agreed to work with the U.S. Food and Drug Administration and other agencies to gather plasma from patients who have recovered from COVID-19 and test potential therapies for the disease, the pharmaceutical firm said on Wednesday.

The plasma will be processed to produce hyperimmune immunoglobins, which will then be put to pre-clinical and clinical tests to see if they can help treat the disease, Grifols said in a statement.

COVID-19 is caused by the coronavirus that is currently sweeping the globe.

Click here for reference